Evidence map›Paper›PMID 29456628›Full record

ArticleBioData mining2018

Identification of influential observations in high-dimensional cancer survival data through the rank product test.

Eunice Carrasquinha, André Veríssimo, Marta B Lopes, Susana Vinga

Abstract read
In one paragraph

Article in BioData mining, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eunice CarrasquinhaIDMEC, Instituto Superior Técnico, Universidade de Lisboa, Rovisco Pais, 1, Lisbon, Portugal.ORCID 0000-0003-3465-4347
André VeríssimoIDMEC, Instituto Superior Técnico, Universidade de Lisboa, Rovisco Pais, 1, Lisbon, Portugal.
Marta B LopesIDMEC, Instituto Superior Técnico, Universidade de Lisboa, Rovisco Pais, 1, Lisbon, Portugal.
Susana VingaIDMEC, Instituto Superior Técnico, Universidade de Lisboa, Rovisco Pais, 1, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvival analysis is a statistical technique widely used in many fields of science, in particular in the medical area, and which studies the time until an event of interest occurs. Outlier detection in this context has gained great importance due to the fact that the identification of long or short-term survivors may lead to the detection of new prognostic factors. However, the results obtained using different outlier detection methods and residuals are seldom the same and are strongly dependent of the specific Cox proportional hazards model selected. In particular, when the inherent data have a high number of covariates, dimensionality reduction becomes a key challenge, usually addressed through regularized optimization, e.g. using Lasso, Ridge or Elastic Net regression. In the case of transcriptomics studies, this is an ubiquitous problem, since each observation has a very high number of associated covariates (genes).

resultsIn order to solve this issue, we propose to use the Rank Product test, a non-parametric technique, as a method to identify discrepant observations independently of the selection method and deviance considered. An example based on the The Cancer Genome Atlas (TCGA) ovarian cancer dataset is presented, where the covariates are patients' gene expressions. Three sub-models were considered, and, for each one, different outliers were obtained. Additionally, a resampling strategy was conducted to demonstrate the methods' consistency and robustness. The Rank Product worked as a consensus method to identify observations that can be influential under survival models, thus potential outliers in the high-dimensional space.

conclusionsThe proposed technique allows us to combine the different results obtained by each sub-model and find which observations are systematically ranked as putative outliers to be explored further from a clinical point of view.

Indexed as

Data dimensionality reductionGene expressionRank product testSurvival analysis

Identifiers

PMID29456628
PMCPMC5813402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.